Affinity Asset Advisors LLC Invests $5.02 Million in Protagonist Therapeutics, Inc. (NASDAQ:PTGX)

Affinity Asset Advisors LLC acquired a new position in shares of Protagonist Therapeutics, Inc. (NASDAQ:PTGX - Free Report) in the fourth quarter, according to its most recent 13F filing with the SEC. The institutional investor acquired 130,000 shares of the company's stock, valued at approximately $5,018,000. Affinity Asset Advisors LLC owned about 0.22% of Protagonist Therapeutics as of its most recent SEC filing.

Other institutional investors and hedge funds have also made changes to their positions in the company. Wellington Management Group LLP bought a new stake in shares of Protagonist Therapeutics during the third quarter valued at approximately $1,354,000. Barclays PLC boosted its position in Protagonist Therapeutics by 223.6% during the 3rd quarter. Barclays PLC now owns 126,995 shares of the company's stock worth $5,714,000 after acquiring an additional 87,755 shares during the period. Geode Capital Management LLC raised its holdings in shares of Protagonist Therapeutics by 0.3% during the third quarter. Geode Capital Management LLC now owns 1,374,697 shares of the company's stock worth $61,873,000 after acquiring an additional 3,528 shares in the last quarter. Teachers Retirement System of The State of Kentucky acquired a new position in shares of Protagonist Therapeutics during the 3rd quarter worth $909,000. Finally, Franklin Resources Inc. grew its holdings in Protagonist Therapeutics by 127.2% during the third quarter. Franklin Resources Inc. now owns 81,591 shares of the company's stock valued at $3,782,000 after purchasing an additional 45,674 shares during the last quarter. 98.63% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

A number of equities analysts have recently commented on the stock. BMO Capital Markets raised their price objective on shares of Protagonist Therapeutics from $62.00 to $72.00 and gave the stock an "outperform" rating in a report on Tuesday, March 11th. The Goldman Sachs Group reduced their target price on Protagonist Therapeutics from $43.00 to $38.00 and set a "neutral" rating on the stock in a report on Monday, February 24th. JMP Securities restated a "market outperform" rating and issued a $58.00 target price on shares of Protagonist Therapeutics in a research note on Friday, February 7th. BTIG Research set a $73.00 price target on Protagonist Therapeutics in a research report on Monday, March 3rd. Finally, HC Wainwright reaffirmed a "buy" rating and issued a $80.00 target price on shares of Protagonist Therapeutics in a report on Thursday, April 10th. Two research analysts have rated the stock with a hold rating, seven have issued a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat, Protagonist Therapeutics currently has a consensus rating of "Moderate Buy" and an average price target of $65.44.

Protagonist Therapeutics Trading Up 1.0 %

Shares of PTGX stock traded up $0.48 during trading hours on Friday, reaching $46.28. 517,389 shares of the company's stock were exchanged, compared to its average volume of 844,270. The stock's 50 day moving average is $44.68 and its 200-day moving average is $42.80. The company has a market cap of $2.84 billion, a price-to-earnings ratio of 17.40 and a beta of 2.30. Protagonist Therapeutics, Inc. has a fifty-two week low of $24.22 and a fifty-two week high of $60.60.

Protagonist Therapeutics (NASDAQ:PTGX - Get Free Report) last issued its quarterly earnings data on Friday, February 21st. The company reported $1.98 earnings per share for the quarter, beating analysts' consensus estimates of ($0.09) by $2.07. Protagonist Therapeutics had a return on equity of 34.68% and a net margin of 52.76%. The company had revenue of $170.64 million during the quarter, compared to analysts' expectations of $56.65 million. Equities analysts anticipate that Protagonist Therapeutics, Inc. will post 2.43 EPS for the current year.

Insiders Place Their Bets

In related news, Director William D. Waddill sold 4,000 shares of the business's stock in a transaction that occurred on Monday, March 17th. The stock was sold at an average price of $54.25, for a total transaction of $217,000.00. Following the completion of the transaction, the director now owns 13,130 shares in the company, valued at $712,302.50. The trade was a 23.35 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, CEO Dinesh V. Ph D. Patel sold 5,359 shares of the company's stock in a transaction dated Wednesday, February 19th. The stock was sold at an average price of $38.18, for a total transaction of $204,606.62. Following the completion of the transaction, the chief executive officer now owns 540,260 shares of the company's stock, valued at approximately $20,627,126.80. This trade represents a 0.98 % decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders sold 64,776 shares of company stock worth $3,585,010. Insiders own 5.40% of the company's stock.

Protagonist Therapeutics Company Profile

Protagonist Therapeutics, Inc, a biopharmaceutical company, develops peptide-based drugs for hematology and blood disorders, and inflammatory and immunomodulatory diseases. It is developing Rusfertide (PTG-300), an injectable hepcidin mimetic that completed phase 2 clinical trials for the treatment of polycythemia vera and other blood disorders; and JNJ-2113, an orally delivered investigational drug to block biological pathways that completed phase 2b clinical trials for the treatment of moderate-to-severe plaque psoriasis; and PN-943, an orally delivered, gut-restricted alpha 4 beta 7 specific integrin antagonist completed a phase 2 clinical trials in patients with moderate to severe ulcerative colitis.